PTGX (Protagonist Therapeutics) Float Percentage Of Total Shares Outstanding: 85.97% (As of Jul. 08, 2026)


PTGX Protagonist Therapeutics Inc PTGX
51 GF Score
Price $140.91
GF Value $61.70
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Protagonist Therapeutics Float Percentage Of Total Shares Outstanding?

Protagonist Therapeutics PTGX +7.11% 51 Float Percentage Of Total Shares Outstanding is 85.97% as of Jul. 08, 2026. GuruFocus rates PTGX with a GF Score™ of 51/100 and a GF Value™ of $61.70 (Significantly Overvalued). The stock has 7 warning signs investors should review.

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Protagonist Therapeutics's float shares is 55.29 Mil. Protagonist Therapeutics's total shares outstanding is 64.31 Mil. Protagonist Therapeutics's float percentage of total shares outstanding is 85.97%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Protagonist Therapeutics's Insider Ownership is 2.03%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Protagonist Therapeutics's Institutional Ownership is 110.88%.

PTGX
51GF Score
Protagonist Therapeutics Inc PTGX
Float Percentage Of Total Shares Outstanding is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Protagonist Therapeutics Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

Protagonist Therapeutics's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding=Float Shares/Total Shares Outstanding
=55.29/64.31
=85.97%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Float Percentage Of Total Shares Outstanding of 85.97% mean?
Protagonist Therapeutics (PTGX) has a Float Percentage Of Total Shares Outstanding of 85.97% as of Jul. 08, 2026. Float percent of shares outstanding equals the percent of float shares relative to total shares. View historical data on Protagonist Therapeutics and its competitors.
Is Protagonist Therapeutics' Float Percentage Of Total Shares Outstanding too high?
Protagonist Therapeutics' current Float Percentage Of Total Shares Outstanding is 85.97%. Overall, Protagonist Therapeutics has a GF Score™ of 51/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Protagonist Therapeutics' Float Percentage Of Total Shares Outstanding compare to IMVT and SYRE?
Protagonist Therapeutics' Float Percentage Of Total Shares Outstanding of 85.97% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Float Percentage Of Total Shares Outstanding for a Biotechnology company?
A good Float Percentage Of Total Shares Outstanding depends on the Biotechnology industry context. However, Float Percentage Of Total Shares Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Float Percentage Of Total Shares Outstanding mean?
A high Float Percentage Of Total Shares Outstanding can signal that a stock is expensive relative to its fundamentals. Float percent of shares outstanding equals the percent of float shares relative to total shares. View historical data on Protagonist Therapeutics and its competitors. Protagonist Therapeutics's current Float Percentage Of Total Shares Outstanding is 85.97%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Protagonist Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Protagonist Therapeutics (PTGX) is currently considered Significantly Overvalued. The stock's GF Value™ is $61.70, compared to a current price of $140.91 — trading 128.4% above its estimated fair value. The current Float Percentage Of Total Shares Outstanding is 85.97%. Protagonist Therapeutics' overall GF Score™ is 51/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Float Percentage Of Total Shares Outstanding calculated?
Float Percentage Of Total Shares Outstanding is calculated from a company's financial statements. For Protagonist Therapeutics (PTGX), the current Float Percentage Of Total Shares Outstanding is 85.97% as of Jul. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Protagonist Therapeutics (PTGX) Overvalued in 2026?

Based on GuruFocus' analysis, Protagonist Therapeutics stock appears to be overvalued. The current stock price of $140.91 is trading 128.4% above its estimated GF Value™ of $61.70. GuruFocus considers Protagonist Therapeutics to be Significantly Overvalued.

Key valuation signals for PTGX:

  • Float Percentage Of Total Shares Outstanding: 85.97%
  • GF Value™: $61.70 vs. price of $140.91 (128.4% above fair value)
  • GF Score™: 51/100 with 7 warning signs

No single metric tells the full story. See the PTGX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Protagonist Therapeutics Business Description

Address 7707 Gateway Boulevard, Suite 140, Newark, CA, USA, 94560
Protagonist Therapeutics Inc is a biopharmaceutical company engaged in the discovery and development of peptide-based therapeutics using its proprietary technology platform. The company focuses on three therapeutic areas: inflammation and immunology, hematology, and metabolic diseases. Its pipeline includes clinical-stage and preclinical candidates such as rusfertide for polycythemia vera, icotrokinra for inflammatory diseases, and other programs targeting IL-17, obesity, and iron metabolism disorders, developed through internal research and strategic collaborations.
51GF Score

Get the complete analysis for PTGX

Float Percentage Of Total Shares Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$140.91
Price
$61.70
GF Value